Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.57 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.57 |
| ▸ | GGH | Q92820 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911001 | 1.00 | FOLH1 (0.57) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL910369 | 1.00 | FOLH1 (0.57) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL22316164 | 0.87 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL2447755 | 0.86 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL25453237 | 0.85 | FOLH1 (0.45) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL21152805 | 0.85 | FOLH1 (0.45) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL18289215 | 0.85 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL4655466 | 0.85 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL14765596 | 0.85 | FOLH1 (0.45) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL4998037 | 0.85 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGHCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023014927-A1 | PRODRUGS OF TAPINAROF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-02-09 | — | — | WO | disclosed |
| CN-113004254-B | Ligand with indocyanine green derivative as carrier, and preparation method and application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
| US-20220183291-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2022-06-16 | — | — | US | disclosed |
| CN-113004254-A | Ligand with indocyanine green derivative as carrier, and preparation method and application thereof | 中国药科大学 | 2021-06-22 | — | — | CN | disclosed |
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
| EP-3804725-A2 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | Rhode Island Hospital (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3220914-B1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL (US) | 2020-09-02 | — | — | EP | disclosed |
| WO-2019201991-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2019-10-24 | — | — | WO | disclosed |
| US-10392412-B2 | Platinum anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-27 | — | — | US | disclosed |
| EP-2049478-B1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8048907-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2011-11-01 | — | — | US | disclosed |
| CN-101969920-A | Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same | SHISEIDO CO LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| EP-0572167-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1996-10-09 | — | — | EP | disclosed |
| EP-0572167-A1 | Cosmestic composition | UNILEVER PLC (GB) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | FOLH1 2259/4885NAALAD2 3287/4885RIMKLA 786/4885 |
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | FOLH1 1057/4885NAALAD2 3593/4885RIMKLA 3050/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | FOLH1 2259/4885NAALAD2 3287/4885RIMKLA 786/4885 |
| US-20220183291-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | IFNG, STING1, IRF3 | FOLH1 3986/4885NAALAD2 1035/4885RIMKLA 3013/4885 |
| US-10392412-B2 | Platinum anticancer agents | TOP2A, TOP1, TP53 | FOLH1 37/4885NAALAD2 1935/4885RIMKLA 2893/4885 |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | FOLH1 4099/4885NAALAD2 1692/4885RIMKLA 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.